233 related articles for article (PubMed ID: 19147760)
1. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
Holzer AK; Katano K; Klomp LW; Howell SB
Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
[TBL] [Abstract][Full Text] [Related]
3. The internalization and degradation of human copper transporter 1 following cisplatin exposure.
Holzer AK; Howell SB
Cancer Res; 2006 Nov; 66(22):10944-52. PubMed ID: 17108132
[TBL] [Abstract][Full Text] [Related]
4. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
6. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
7. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
8. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
10. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
12. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
Kuo MT; Fu S; Savaraj N; Chen HH
Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters.
Guo Y; Smith K; Petris MJ
J Biol Chem; 2004 Nov; 279(45):46393-9. PubMed ID: 15326162
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
[TBL] [Abstract][Full Text] [Related]
16. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
17. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.
Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT
J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751
[TBL] [Abstract][Full Text] [Related]
19. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB
J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158
[TBL] [Abstract][Full Text] [Related]
20. Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2011 Sep; 31(9):2757-62. PubMed ID: 21868517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]